News and Articles - Arthramid

Arthramid in the joint

Filter:

Chance's Arthramid testimonial

How Arthramid Helped a Rescued Pony Rewrite His Future

The Myth of Neurotoxicity: What the Science Really Says About 2.5% iPAAG

The Myth of Neurotoxicity: What the Science Really Says About 2.5% iPAAG

jill Haas, Western rider

A Game Changer for Western Performance Horses

Retrospective analysis of the long-term use of 2.5% injectable polyacrylamide hydrogel (2.5% iPAAG) in a Thoroughbred racehorse practice: Safety on 701 horses, Efficacy on 214 horses

Retrospective analysis of the long-term use of 2.5% injectable polyacrylamide hydrogel (2.5% iPAAG) in a Thoroughbred racehorse practice: Safety on 701 horses, Efficacy on 205 horses

Retrospective analysis of the long-term use of 2.5% iPAAG in sport horse practice: Safety on 1000 horses, efficacy on 252 horses

Retrospective analysis of the long-term use of 2.5% iPAAG in sport horse practice: Safety on 1000 horses, efficacy on 252 horses

arthramid for stifle

A Second Chance: How Arthramid Gave Ciao Bella a New Lease on Life

Arthramid packaging

Arthramid 2.5% iPAAG: A Game-Changer for Joint Disease. A Vet’s Guide to Accessing It Legally in Europe.

arthramid for stifle

Joint Spotlight: The Stifle

Joint Spotlight: The Hock

Canine Arthramid testimonial

Fighting Canine Arthritis: How Arthramid Gave Sophie a New Lease on Life

Physicochemical Properties of 2.5% iPAAG

The Unique Physicochemical Properties of 2.5% Injectable Polyacrylamide Hydrogel (iPAAG) in Joint Lameness Treatment

Excitement at the EU Vet KOL Group Meeting: Celebrating Arthramid’s Success and Future Prospects

READ

Talk to us for more information

Contact Us